Artiva Biotherapeutics Inc
NASDAQ:ARTV

Watchlist Manager
Artiva Biotherapeutics Inc Logo
Artiva Biotherapeutics Inc
NASDAQ:ARTV
Watchlist
Price: 11.2 USD 2.99% Market Closed
Market Cap: 272m USD
Have any thoughts about
Artiva Biotherapeutics Inc?
Write Note

Intrinsic Value

The intrinsic value of one ARTV stock under the Base Case scenario is 5.38 USD. Compared to the current market price of 11.2 USD, Artiva Biotherapeutics Inc is Overvalued by 52%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ARTV Intrinsic Value
5.38 USD
Overvaluation 52%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Artiva Biotherapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ARTV cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ARTV?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Artiva Biotherapeutics Inc

Provide an overview of the primary business activities
of Artiva Biotherapeutics Inc.

What unique competitive advantages
does Artiva Biotherapeutics Inc hold over its rivals?

What risks and challenges
does Artiva Biotherapeutics Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Artiva Biotherapeutics Inc.

Provide P/S
for Artiva Biotherapeutics Inc.

Provide P/E
for Artiva Biotherapeutics Inc.

Provide P/OCF
for Artiva Biotherapeutics Inc.

Provide P/FCFE
for Artiva Biotherapeutics Inc.

Provide P/B
for Artiva Biotherapeutics Inc.

Provide EV/S
for Artiva Biotherapeutics Inc.

Provide EV/GP
for Artiva Biotherapeutics Inc.

Provide EV/EBITDA
for Artiva Biotherapeutics Inc.

Provide EV/EBIT
for Artiva Biotherapeutics Inc.

Provide EV/OCF
for Artiva Biotherapeutics Inc.

Provide EV/FCFF
for Artiva Biotherapeutics Inc.

Provide EV/IC
for Artiva Biotherapeutics Inc.

Show me price targets
for Artiva Biotherapeutics Inc made by professional analysts.

What are the Revenue projections
for Artiva Biotherapeutics Inc?

How accurate were the past Revenue estimates
for Artiva Biotherapeutics Inc?

What are the Net Income projections
for Artiva Biotherapeutics Inc?

How accurate were the past Net Income estimates
for Artiva Biotherapeutics Inc?

What are the EPS projections
for Artiva Biotherapeutics Inc?

How accurate were the past EPS estimates
for Artiva Biotherapeutics Inc?

What are the EBIT projections
for Artiva Biotherapeutics Inc?

How accurate were the past EBIT estimates
for Artiva Biotherapeutics Inc?

Compare the revenue forecasts
for Artiva Biotherapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Artiva Biotherapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Artiva Biotherapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Artiva Biotherapeutics Inc compared to its peers.

Compare the P/E ratios
of Artiva Biotherapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Artiva Biotherapeutics Inc with its peers.

Analyze the financial leverage
of Artiva Biotherapeutics Inc compared to its main competitors.

Show all profitability ratios
for Artiva Biotherapeutics Inc.

Provide ROE
for Artiva Biotherapeutics Inc.

Provide ROA
for Artiva Biotherapeutics Inc.

Provide ROIC
for Artiva Biotherapeutics Inc.

Provide ROCE
for Artiva Biotherapeutics Inc.

Provide Gross Margin
for Artiva Biotherapeutics Inc.

Provide Operating Margin
for Artiva Biotherapeutics Inc.

Provide Net Margin
for Artiva Biotherapeutics Inc.

Provide FCF Margin
for Artiva Biotherapeutics Inc.

Show all solvency ratios
for Artiva Biotherapeutics Inc.

Provide D/E Ratio
for Artiva Biotherapeutics Inc.

Provide D/A Ratio
for Artiva Biotherapeutics Inc.

Provide Interest Coverage Ratio
for Artiva Biotherapeutics Inc.

Provide Altman Z-Score Ratio
for Artiva Biotherapeutics Inc.

Provide Quick Ratio
for Artiva Biotherapeutics Inc.

Provide Current Ratio
for Artiva Biotherapeutics Inc.

Provide Cash Ratio
for Artiva Biotherapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Artiva Biotherapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Artiva Biotherapeutics Inc?

What is the current Free Cash Flow
of Artiva Biotherapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Artiva Biotherapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Artiva Biotherapeutics Inc

Balance Sheet Decomposition
Artiva Biotherapeutics Inc

Current Assets 104.7m
Cash & Short-Term Investments 102.5m
Receivables 525k
Other Current Assets 1.6m
Non-Current Assets 28.4m
PP&E 27.6m
Other Non-Current Assets 762k
Current Liabilities 25.6m
Accounts Payable 1.1m
Accrued Liabilities 13.6m
Other Current Liabilities 10.9m
Non-Current Liabilities 31.7m
Other Non-Current Liabilities 31.7m
Efficiency

Earnings Waterfall
Artiva Biotherapeutics Inc

Revenue
33.5m USD
Operating Expenses
-64.2m USD
Operating Income
-30.7m USD
Other Expenses
2m USD
Net Income
-28.7m USD

Free Cash Flow Analysis
Artiva Biotherapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ARTV Profitability Score
Profitability Due Diligence

Artiva Biotherapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Exceptional 1-Year Revenue Growth
Negative Operating Income
Negative Net Income
Negative ROE
21/100
Profitability
Score

Artiva Biotherapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

ARTV Solvency Score
Solvency Due Diligence

Artiva Biotherapeutics Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
62/100
Solvency
Score

Artiva Biotherapeutics Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ARTV Price Targets Summary
Artiva Biotherapeutics Inc

Wall Street analysts forecast ARTV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ARTV is 21.68 USD with a low forecast of 18.18 USD and a high forecast of 24.15 USD.

Lowest
Price Target
18.18 USD
62% Upside
Average
Price Target
21.68 USD
94% Upside
Highest
Price Target
24.15 USD
116% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ARTV?

Click here to dive deeper.

Dividends

Artiva Biotherapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ARTV is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Artiva Biotherapeutics Inc Logo
Artiva Biotherapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

270.9m USD

Dividend Yield

0%

Description

Artiva Biotherapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 81 full-time employees. The company went IPO on 2024-07-19. Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. The firm's product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as LN, RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, SLE and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.

Contact

CALIFORNIA
San Diego
5505 Morehouse Drive
+18582674467
www.artivabio.com

IPO

2024-07-19

Employees

81

Officers

President, CEO & Director
Dr. Fred Aslan M.D.
Co-Founder & Strategic Advisor
Dr. Peter Flynn Ph.D.
Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer
Ms. Jennifer Kinsbruner Bush Esq., J.D.
Chief Technical Operations Officer
Mr. Christopher P. Horan
Chief Medical Officer
Dr. Thorsten Graef M.D., Ph.D.
Senior Vice President of Research & Early Development
Dr. Heather Raymon Ph.D.
Show More
Senior VP of Medical Affairs
Mr. Javier Coindreau M.D.
Senior VP of Clinical Operations
Dr. David Moriarty Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one ARTV stock?

The intrinsic value of one ARTV stock under the Base Case scenario is 5.38 USD.

Is ARTV stock undervalued or overvalued?

Compared to the current market price of 11.2 USD, Artiva Biotherapeutics Inc is Overvalued by 52%.

Back to Top